EA201892635A1 - Иммуномодуляторы для пэт-визуализации - Google Patents

Иммуномодуляторы для пэт-визуализации

Info

Publication number
EA201892635A1
EA201892635A1 EA201892635A EA201892635A EA201892635A1 EA 201892635 A1 EA201892635 A1 EA 201892635A1 EA 201892635 A EA201892635 A EA 201892635A EA 201892635 A EA201892635 A EA 201892635A EA 201892635 A1 EA201892635 A1 EA 201892635A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunodulators
visualization
pet
disease
pet visualization
Prior art date
Application number
EA201892635A
Other languages
English (en)
Other versions
EA038019B1 (ru
Inventor
Дэвид Дж. Доннелли
Кеннет М. Бой
Юньхуай Чжан
Джониюн Ким
Адриенне Пена
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201892635A1 publication Critical patent/EA201892635A1/ru
Publication of EA038019B1 publication Critical patent/EA038019B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к синтезу и применению милламолекул, меченныхF, для визуализации различных процессов в организме, для обнаружения местоположения молекул, связанных с патологией заболевания, и для мониторинга развития заболевания.
EA201892635A 2016-05-19 2017-05-17 Иммуномодуляторы для пэт-визуализации EA038019B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (2)

Publication Number Publication Date
EA201892635A1 true EA201892635A1 (ru) 2019-04-30
EA038019B1 EA038019B1 (ru) 2021-06-23

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892635A EA038019B1 (ru) 2016-05-19 2017-05-17 Иммуномодуляторы для пэт-визуализации

Country Status (24)

Country Link
US (2) US11103605B2 (ru)
EP (2) EP3458111B1 (ru)
JP (1) JP6953444B2 (ru)
KR (1) KR102378288B1 (ru)
CN (1) CN109414514B (ru)
AU (1) AU2017268291B2 (ru)
BR (1) BR112018073642A2 (ru)
CA (1) CA3024844A1 (ru)
CY (1) CY1124241T1 (ru)
DK (1) DK3458111T3 (ru)
EA (1) EA038019B1 (ru)
ES (1) ES2864091T3 (ru)
HR (1) HRP20210644T8 (ru)
HU (1) HUE054306T2 (ru)
IL (1) IL262962B (ru)
LT (1) LT3458111T (ru)
MA (1) MA53402A (ru)
MX (1) MX2018014028A (ru)
PL (1) PL3458111T3 (ru)
PT (1) PT3458111T (ru)
RS (1) RS61742B1 (ru)
SG (1) SG11201810177VA (ru)
SI (1) SI3458111T1 (ru)
WO (1) WO2017201111A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
AU2017367734A1 (en) 2016-12-01 2019-06-20 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging
WO2018119313A1 (en) 2016-12-23 2018-06-28 The Johns Hopkins University Tumor and immune cell imaging based on pd-l1 expression
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
CN115485288A (zh) * 2020-03-16 2022-12-16 百时美施贵宝公司 免疫调节剂
US20220405917A1 (en) * 2021-06-18 2022-12-22 Case Western Reserve University Combination of features from biopsies and scans to predict prognosis in sclc
WO2024129479A2 (en) * 2022-12-12 2024-06-20 Merck Sharp & Dohme Llc Cyclic peptides as pet imaging agents of granzyme b

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
DE69737867T2 (de) 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US6126916A (en) 1996-07-12 2000-10-03 Immunomedics, Inc. Radiometal-binding peptide analogues
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
JP3992923B2 (ja) 1997-09-03 2007-10-17 イムノメディクス， インコーポレイテッド Ｆ−１８陽電子放出トモグラフィー用のタン白及びペプチドのフッ素化方法
EP2990411B1 (en) 2007-03-26 2017-05-03 The University of Tokyo Process for synthesizing cyclic peptide compound
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
EP2647720B1 (en) 2010-12-03 2019-06-19 The University of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
JP2015512910A (ja) 2012-03-29 2015-04-30 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
IN2014KN02752A (ru) 2012-06-06 2015-05-08 Polyphor Ag
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
KR20230070054A (ko) 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
LT3041468T (lt) 2013-09-06 2018-10-25 Aurigene Discovery Technologies Limited Cikliniai peptidomimetiniai junginiai kaip imunomoduliatoriai
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
AU2014405919B2 (en) 2014-09-11 2020-02-20 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80 (B7-1)/PD-Li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
JP6701217B2 (ja) 2014-11-25 2020-05-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 生物学的製剤の１８ｆ−放射性標識方法および組成物
EP3702367B1 (en) * 2014-11-25 2024-05-15 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN110267971B (zh) 2016-11-07 2023-12-19 百时美施贵宝公司 免疫调节剂
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂

Also Published As

Publication number Publication date
JP2019520328A (ja) 2019-07-18
PT3458111T (pt) 2021-04-09
BR112018073642A2 (pt) 2019-02-26
MX2018014028A (es) 2019-04-04
WO2017201111A1 (en) 2017-11-23
RS61742B1 (sr) 2021-05-31
LT3458111T (lt) 2021-05-25
US20210386876A1 (en) 2021-12-16
US20190117801A1 (en) 2019-04-25
MA53402A (fr) 2021-06-02
HUE054306T2 (hu) 2021-08-30
PL3458111T3 (pl) 2021-06-28
AU2017268291B2 (en) 2022-09-29
EP3827849A1 (en) 2021-06-02
JP6953444B2 (ja) 2021-10-27
ES2864091T3 (es) 2021-10-13
US11103605B2 (en) 2021-08-31
HRP20210644T1 (hr) 2021-05-28
CN109414514B (zh) 2022-03-11
AU2017268291A1 (en) 2019-01-17
SG11201810177VA (en) 2018-12-28
EA038019B1 (ru) 2021-06-23
CN109414514A (zh) 2019-03-01
HRP20210644T8 (hr) 2021-06-25
EP3458111B1 (en) 2021-03-03
EP3458111A1 (en) 2019-03-27
DK3458111T3 (da) 2021-04-26
KR20190009330A (ko) 2019-01-28
IL262962A (en) 2018-12-31
CY1124241T1 (el) 2022-07-22
IL262962B (en) 2020-04-30
SI3458111T1 (sl) 2021-07-30
CA3024844A1 (en) 2017-11-23
KR102378288B1 (ko) 2022-03-23

Similar Documents

Publication Publication Date Title
EA201892635A1 (ru) Иммуномодуляторы для пэт-визуализации
EA201791167A1 (ru) Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
ECSP16081503A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MX2019005748A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
EA202092435A3 (ru) Моноклональные антитела против bcma
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112015032031A2 (pt) métodos e processos para avaliação não invasiva das variações genéticas
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
UY39848A (es) Procesos para la preparación de un agente inductor de la apoptosis
CY1120459T1 (el) Αντισωματα των χημειοκινων παν-elr+ cxc
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
ES2540255A1 (es) Método de aislamiento de cuerpos apoptóticos
BR112016006556A2 (pt) arranjos detectáveis, sistemas para diagnóstico, e métodos para produzir e usar os mesmos
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
BR112017011543A2 (pt) peptídeos cíclicos derivados de cd44v6 para o tratamento de cânceres e doenças relacionadas à angiogênese
BR112018003800A2 (pt) derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização
EA201890632A1 (ru) Хиральные фосфорамидимидаты и их производные
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона
TR201906876T4 (tr) Amniyotik sıvının tanımlanması için tanısal kompozisyon.
JP2016064626A5 (ru)